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The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all
widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have char-
acterized a set of 106 clinical isolates ofMycobacterium tuberculosis using phenotypic drug susceptibility testing
(DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results
were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated
in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six
(34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36)
showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms
in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no
known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST signifi-
cantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum
conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the
National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for esti-
mating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and cross-
resistance among these agents and suggest that the development of rapid molecular tests to distinguish
polymorphisms would significantly enhance clinical utility of this important class of second-line antitubercu-
losis drugs.
Drug-resistant tuberculosis (TB) is an emerging issue in
global TB control, with multidrug-resistant (MDR) and exten-
sively drug-resistant (XDR) disease threatening to overwhelm
existing initiatives (8). The difference between MDR TB (re-
sistant to at least isoniazid [INH] and rifampin [RIF]) and
XDR TB (MDR plus resistant to any fluoroquinolone and at
least one of the injectable second-line drugs amikacin [AK],
kanamycin [KM], and capreomycin [CM]) is often life or death
for patients suffering from drug-resistant TB (7, 14, 15). None-
theless, the diagnosis of MDR and XDR TB remains a lengthy,
technically demanding laboratory procedure relying on cultur-
ing bacteria isolated from patient sputum on solid or liquid
medium in the presence of individual drugs. To make matters
worse, such highly resistant strains occasionally show growth
differences in in vitro culture that may be related to fitness costs
imposed by the mutations conferring resistance (9). These
growth differences, and the complexity of in vitro assessment of
drug resistance, result in laboratory determinations of XDR of
questionable reliability (16). There is a growing movement
toward molecular drug susceptibility testing using a variety of
detection platforms that show robust performance for the first-
line agents that define MDR TB (10).
Molecular drug susceptibility tests are limited in accuracy
only by knowledge of the single nucleotide polymorphisms
(SNPs) associated with conferring drug resistance. Since these
are relatively well defined for the two front-line agents, INH
and RIF, such tests perform well for these two agents, and one
has even recently received regulatory approval for use in the
diagnosis of MDR TB (3, 12, 18). The performance of molec-
ular DST for the diagnosis of XDR TB is far inferior to that for
the diagnosis of MDR TB principally due to the lack of de-
tailed knowledge of the SNPs associated with resistance (11).
The SNPs associated with fluoroquinolone resistance are
somewhat established, and the sensitivities of such tests have
been reported to range from 70 to 90% (2, 21, 28).
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Far less is known about the mechanisms by which TB devel-
ops resistance to aminoglycosides, including KM, AK, and
streptomycin (SM). Despite the knowledge that the molecular
target of all three is the bacterial ribosome, and despite the
availability of the three-dimensional structure of the ribosome
in complex with several aminoglycosides, we still lack a basic
understanding of which mutations confer which patterns of
resistance and cross-resistance in isolates from patients (6). In
addition, CM, a structurally unrelated cyclic polypeptide, also
binds the bacterial ribosome and there is relatively little infor-
mation relating cross-resistance between the aminoglycosides
and this class of molecule. In one study of 17 drug-resistant
clinical isolates, 13 were found to have a SNP in the rrs gene
(A1401G) and all 13 were found to be fully cross-resistant to
KM, AK, and SM, while there were no polymorphisms to
which to attribute the resistance of the remaining 4 isolates (1).
In another study of 16 drug-resistant clinical isolates, 9 were
identified as having exclusively the same rrs(A1401G) SNP
while 5 other strains had multiple rrs polymorphisms and the
remaining 2 had none. Levels of cross-resistance depended on
the exact SNPs in each strain, with at least one strain appearing
cross-resistant to CM as well as KM and AK (19). In a study of
18 CM-resistant mutants selected in vitro by transposition, an
rRNA methyltransferase encoded by tlyA was implicated in
CM resistance, with 4 of these isolates retaining full suscepti-
bility to KM and AK (20). More recently, polymorphisms in
gidB, another rRNA methyltransferase, were found to be
closely associated with low-level SM resistance (20). These
authors report that of 132 randomly selected clinical isolates,
57 were SM resistant and most contained polymorphisms in
the gidB gene. Interestingly, 22 of the 57 SM-resistant isolates
were also resistant to KM but did not contain the rrs(A1401G)
SNP, thereby suggesting that gidB polymorphisms may mediate
some level of cross-resistance between SM and KM.
In this study we examine the cross-resistance, molecular
genetics, and outcomes of therapy for 106 subjects, most of
whom were undergoing retreatment with second-line antitu-
bercular agents. These subjects are part of an ongoing, longi-
tudinal study of the factors that contribute to the development,
diagnosis, and cure of XDR TB (13).
MATERIALS AND METHODS
Mycobacterium tuberculosis strains and clinical isolates. The M. tuberculosis
strain H37Rv was used as a standard in all experiments. Clinical isolates included
in this analysis were collected from subjects sequentially enrolled in cohort B of
a prospective observational cohort study (ClinicalTrials.gov identifier:
NCT00341601) conducted in collaboration with the National Masan Tuberculo-
sis Hospital (NMTH), a tertiary TB care center in South Korea. The character-
istics of the subjects enrolled in this study and who yielded these isolates have
been previously described by Jeon et al. (13). Cohort B enrolled consenting
subjects with more than 30 days of previous treatment prior to their current
diagnosis of TB. While all subjects enrolled in the trial were sputum smear
positive for acid-fast bacilli (AFB), some had begun treatment prior to enroll-
ment; thus, not all subjects yielded cultivable M. tuberculosis. The 106 isolates
described here were isolated from the first postenrollment sputum samples
provided by 145 subjects enrolled in cohort B. Among 39 subjects whose samples
not evaluated in this study, 1 subject withdrew prior to producing a sputum
sample, and specimens from another 24 subjects were not successfully cultured
initially. In addition, 3 isolates were identified as nontuberculous mycobacteria
and 11 did not grow consistently on 7H10 agar supplemented with oleic acid
albumin complex upon attempted resuscitation from frozen stocks.
The cohort study that yielded these isolates was reviewed and approved by the
Institutional Review Boards of the NMTH and by the National Institute of
Allergy and Infectious Disease, National Institutes of Health. All subjects gave
written informed consent. Data collection, quality, and protocol compliance were
monitored by an independent clinical research organization.
Drug susceptibility testing. The clinical laboratory of NMTH (lab A) performs
drug susceptibility testing (DST) using the absolute concentration method on
Lo¨wenstein-Jensen (LJ) slants containing the relevant anti-TB drugs (4, 5), and
these data are collected as part of this observational study. Growth of more than
1% of the control in LJ medium indicated resistance. Isolates were tested for
resistance to INH (0.2 g/ml), RIF (40 g/ml), ethambutol (EMB) (2.0 g/ml),
SM (10 g/ml), KM (40 g/ml), ofloxacin (OFX) (2.0 g/ml), ethionamide
(ETH) (40 g/ml), cycloserine (CS) (30 g/ml), and p-aminosalicylic acid (PAS)
(1 g/ml). Resistance to pyrazinamide (PZA) was determined by the pyrazin-
amidase assay (29).
The MICs of KM (5 to 160 g/ml), AK (4 to 64 g/ml), CM (10 to 160 g/ml),
and SM (4 to 64 g/ml) were determined for each isolate using the current
standard for susceptibility testing using Middlebrook 7H10 agar in labs B (In-
ternational Tuberculosis Research Center) and C (Yonsei University College of
Medicine) using the agar proportion method as described by the National Com-
mittee for Clinical Laboratory Standards (NCCLS). The MIC was defined as the
lowest concentration of drug resulting in growth of 1% of the inoculum.
When conflicting results were observed between lab A and lab B (25% of the
strains for SM and 7% of the strains for KM), repeated MIC measurements for
each isolate were performed in lab C using the NCCLS method and all four
drugs. If the two NCCLS determinations were in agreement, then that was the
MIC reported for that strain. If the NCCLS method performed in lab C dis-
agreed with that from lab B but agreed with the result of the absolute concen-
tration method test done in lab A, then the MIC was repeated again in lab C and
the MIC reported accordingly. In addition, lab C randomly repeated an addi-
tional 25 strains with concordant results (between lab A and lab B) all of which
agreed with the original determination.
Genotyping and DNA sequencing. DNA samples were prepared as described
previously (17). Direct sequencing of the rpsL, rrs(420-980), rrs(1293-1537), tlyA,
and gidB genes was performed on PCR products obtained from amplification of
chromosomal DNA with the primers shown in Table 1. Both DNA strands of the
resulting PCR products were sequenced. The BLAST2 sequence database avail-
able from the National Center for Biotechnology Information (NCBI, NIH,
Bethesda, MD) was used for DNA sequence comparison.
Statistical methods. The Fisher exact test was used to compare the propor-
tions of drug-resistant and drug-sensitive isolates with the SNPs of interest, and
the odds ratios (OR), 95% confidence intervals (CI), and P values were calcu-
lated using Prism 5 (GraphPad Prism Software). The Fisher exact test with
calculations for sensitivity, selectivity, and likelihood analysis was used to com-
pare predictive ability of the DST methods with subject sputum culture conver-
sion.
RESULTS
Phenotypic drug susceptibility testing for the aminoglyco-
sides and CM. We have analyzed 106 isolates from consecu-
TABLE 1. Sequences of primers used
Gene (annealing temp) Forward primer Reverse primer
rrs-1F, 1R (60°C) 5 TCCTTAAAAGCCGGTCTCAG 5 ACAGACAAGAACCCCTCACG
rrs-420F, 990R (65°C) 5 TTCACCATCGACGAAGGTCC 5 CTAGACGCGTCCTGTGCATGT
tlyA-1F, 1R (60°C) 5 CATCGCACGTCGTCTTTC 5 AATACTTTTTCTACGCGCCG
rpsL-1F, 1R (60°C) 5 GGCCGACAAACAGAACGT 5 GTTCACCAACTGGGTGAC
gidB-1F, 1R (58°C) 5 CGTAATGTCTCCGATCGAGC 5 CTTTGATGGCGAGCATTCG
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tively enrolled South Korean subjects with a history of at least
30 days of prior TB chemotherapy. These subjects were se-
lected from our ongoing longitudinal study of MDR and XDR
TB from a tertiary referral hospital that specializes in the
treatment of patients with highly drug-resistant strains (13).
From this sample, 73 (68%) isolates were resistant to both INH
and RIF (MDR); among these, 18 isolates were pre-XDR
(being resistant to either KM or a fluoroquinolone but not
both) and 14 (13%) fit the formal definition of XDR TB (23).
All but one of the isolates were found to be members of the
Beijing clade by spoligotyping, and many had atypical Beijing
restriction fragment length polymorphism patterns (data not
shown). To determine susceptibility to SM, KM, AK, and CM,
we first obtained susceptibility data for SM and KM using the
absolute concentration method on LJ slants (lab A) from the
medical chart (5). This testing method, however, does not
provide quantitative information on the MIC of each of these
agents. Therefore, we performed MIC testing in a second lab-
oratory (lab B) using the standard agar proportion method as
described by the NCCLS (30). Because we observed discor-
dance between these two sets of results for 25% of the strains
tested with respect to SM resistance and with 7% of the strains
tested with respect to KM resistance, we repeated the MICs for
the discordant strains along with random concordant strains in
a third laboratory (lab C) in order to achieve consensus. We
consistently observed poorer concordance between laborato-
ries with SM than with KM, a finding that held true even when
comparing results from the same lab (lab C) repeating the
susceptibility testing another time (Table 2). Concordance be-
tween lab B and lab C for results from AK and CM was above
90% for both drugs. Consensus MICs were obtained as de-
scribed in Materials and Methods. Our results showed, as ex-
pected, that about 20% of the isolates were resistant to various
levels of each of the four agents tested (Table 3).
Polymorphisms in genes encoding components of the myco-
bacterial 16S ribosome. From this set of 106 isolates we se-
quenced the entire rpsL-encoded ribosomal S12 protein as well
as the central domain (nucleotides 420 to 980) and the 3
minor domain (nucleotides 1293 to 1537) of the 16S rRNA
encoded by the rrs gene (Table 3). Among these isolates, 12
contained an A3G transition at nucleotide (nt) 128 of rpsL
resulting in the mutation of lysine 43 to arginine in the RpsL
protein. Two other strains with rpsL SNPs were observed; one
had a T3C transition at nt 51, and the other had an A3G
transition at nt 363, both of which were silent with respect to
altering amino acid composition.
The 3 minor domain of the rRNA encoded by rrs was found
to have polymorphisms in 28 isolates from this strain collec-
tion. As expected, alteration of nt 1401 in helix 44 of the
mature rRNA was by far the most common, with an A3G
transition occurring in all 16 of the isolates in which any alter-
ation was found in this region. A second SNP in this domain
was also found at high frequency. In 16 isolates an A3C
transversion was observed at nt 1338, which occupies a position
at the base of helix 43 in the rRNA structure. In addition, a
single strain had SNPs in nearby nt 1332 (helix 29) and 1445
(helix 44).
Seven isolates were found to have SNPs in the rRNA central
domain that includes both the 530 loop region of helix 18 and
a region in helix 26. Five isolates had SNPs in nt 514; four had
A3C transversions, while one showed an A3T transversion.
In the same loop at the tip of helix 18, two other isolates
showed 517 C3T transitions. No SNPs were detected in the
900 region of helix 27; however, a single strain showed a C3T
transition at nt 832.
The correlation between ribosomal gene polymorphisms
and SM resistance. To understand the relationship between
the observed polymorphisms and the DST results, we com-
pared the distribution of SNPs between SM-resistant and SM-
sensitive strains at each allele (Fig. 1A). More than 20% of the
106 isolates were resistant to 8 g/ml or more SM. Among 80
SM-susceptible isolates, SNPs at nt 128 in the rpsL gene were
never observed, while among 15 isolates showing high-level SM
resistance (64 g/ml), 12 showed an A3G transition result-
ing in the replacement of the wild-type lysine by arginine at
position 43 in the protein. Thus, rpsL(A128G) appears to be
associated with high-level SM resistance as expected (OR 
138.8, 95% CI  7.774 to 2.478, P  0.0001). The remaining
two observed SNPs in rpsL (nt 363 A3G and nt 51 T3C) were
also found in isolates that were fully sensitive to SM.
In the rrs gene the A3G transition at nt 1401 was observed
in 8 out of 80 fully SM-susceptible isolates, as well as 4 out of
11 moderately resistant strains and 4 out of 15 highly resistant
strains. A similar pattern of distribution characterizes polymor-
phisms at nt 1338, which are also found in both SM-susceptible
and SM-resistant isolates, suggesting no correlation with resis-
tance. Seven isolates having SNPs in helix 18 were identified at
nt 514 and 517. These SNPs were found in 4 out of 11 and 2 out
of 15 strains that were moderately or highly SM resistant,
respectively. Interestingly, one of these SNPs occurred in an
isolate that was SM susceptible by the agar proportion method.
However, this isolate was scored as SM resistant by the abso-
lute concentration method and this result was repeated several
times with comparable outcomes. Thus, all seven isolates con-
taining changes in the pseudoknot region of helix 18 were SM
resistant to some extent. Three additional rrs singleton SNPs
were observed, one at nt 832 in helix 26 in a SM-resistant strain
that was also carrying a SNP at rrs 514 and two others at nt
1332 and 1445, both of which occurred in the same moderately
SM-resistant isolate (32 g/ml). Thus, from this data, two re-
gions of rrs, the pseudoknot region of helix 18 (OR  23.7,
95% CI  2.7 to 208, P  0.008) and the 3 domain, including
both helix 44 and helix 26 (OR  4, 95% CI  1.3 to 12.1, P 
0.022), are likely to be associated with SM resistance.
TABLE 2. Concordance of drug susceptibility testing between and
within labs
Lab
% concordancec
Lab Aa Lab Bb Lab Cb
SM KMc SM KM SM KM
Lab A
Lab B 75 93
Lab C 63 91 83 92 85 100
a Drug susceptibility testing determined via the absolute concentration method
on LJ slants (4).
b Drug susceptibility testing determined via the agar proportion method per
NCCLS standards.
c Percentages of isolates whose DST results were concordant between the two
labs. SM, streptomycin; KM, kanamycin.
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The correlation between ribosomal gene polymorphisms
and KM/AK resistance. KM and AK resistance appeared to be
almost identical across the entire set of strains in which poly-
morphisms were found; therefore, the data were analyzed for
correlation with SNPs simultaneously for KM and AK (Fig. 2).
Eight strains that were fully susceptible to KM/AK had SNPs in
the rpsL gene at nt 128, while only 4 out of the 16 that were
highly resistant to KM/AK showed such SNPs and all 4 of these
strains contained both the rrs(A1401G) allele and the
rpsL(A128G) allele and were also highly resistant to SM (Table
3). The two other SNPs in rpsL observed occurred in KM- or
AK-susceptible strains. Therefore, we found little evidence of
an association between any rpsL gene SNP and resistance to
KM/AK (OR  2.4, 95% CI  0.7 to 9.1, P  0.22).
Sixteen isolates were identified that had SNPs in rrs in the
region of nt 1401, and all were highly resistant to KM/AK; in
contrast, this SNP in helix 44 was never found in a KM/AK-
susceptible strain. Therefore, as expected, there was a strong
correlation between KM/AK resistance and the presence of
the rrs(A1401G) allele (OR  619, 95% CI  31.8 to 12,075,
P  0.0001) (Fig. 1B). Similar to what was observed for SM,
the 16 SNPs observed at nt 1338 occurred in both susceptible
and KM/AK-resistant isolates, without an apparent strong as-
sociation with drug-resistant strains (OR 2.2, 95% CI 0.69
to 7.5, P  0.178). Further, the 1338 A3C transversion was
observed in eight fully drug-susceptible isolates, suggesting
that this SNP at the base of helix 43 may not be associated with
resistance to any of these agents. Five out of seven isolates
showing SNPs in the pseudoknot region of helix 18
[rrs(A514C), rrs(A514T), and rrs(C517T)] were fully KM/AK
susceptible, and the remaining two isolates were also SM re-
sistant. Therefore, polymorphisms in this region do not appear
to be associated with KM/AK resistance (OR  0.70, 95%
CI  0.08 to 6.1, P  1). Likewise the isolate containing the
SNP in helix 26 (nt 832) was also KM/AK sensitive. The
strain carrying the double SNPs rrs(A1445G, G1332A) was
TABLE 3. Polymorphisms in the rrs, rpsL, and gidB genes of TB clinical isolates
Phenotypic
resistance pattern
Polymorphism in gene No. of
isolates
Drug MIC (g/ml) (no. of strains)
rrs rpsL gidBa KM AK CM SM
KM/AK/CM/SM 514 A3C, 1338 A3C,
1401 A3G
1 80 64 20 32
1332 G3A, 1445
A3G
1 20 32 160 32
1401 A3G 128 A3G (K3R) 4 80 64 20 (2); 160 (2) 64
1401 A3G, 1338
A3C
G102 2 80 64 40 8
1401 A3G 254 A3G (D3G) 1 80 64 80 8
KM/AK/CM 1338 A3C, 1401
A3G
2 160 64 40 4
1401 A3G G102;
230 T3C (V3A);
104 T3G (L3R);
286 C3T (R3C)
4 80 64 20 (2); 40 (2) 4
1401 A3G 2 80 64 20 (1); 80 (1) 4
KM/CM/SM 514 A3C 1 10 4 40 64
KM NMb NM 341 T3C (I3T); C115 2 10 (1); 40 (1) 4 10 4
SM 128 A3G (K3R) 7 5 4 10 64
514 A3T 1 5 4 10 64
514 A3C, 832 C3T 1 5 4 10 8
517 C3T 1 5 4 10 64
517 C3T, 1338 A3C 1 5 4 10 16
1338 A3C 128 A3G (K3R) 1 5 4 10 64
1338 A3C 341 T3C (I3T) 1 5 4 10 8
1338 A3C 440 A3C (K3T) 1 5 4 10 8
169 G3T (stop) 1 5 4 10 32
NM NM NM 1 5 4 10 64
Sensitive 1338 A3C 6 5 4 10 4
514 A3C 1 5 4 10 4
1338 A3C G193;
278 C3A (P3Q)
2 5 4 10 4
51 T3C; 363
A3Gc
2 5 4 10 4
G102; C115;
133 T3C (W3R);
251 C3G (P3R);
254 A3G (D3G);
413 C3T (A3V);
413 C3A (A3E)
8 5 4 10 4
NM NM NM 51 5 4 10 4
a All of the gidB polymorphisms occur as single polymorphisms in individual strains but are grouped for brevity.
b NM, no mutation.
c Both polymorphisms are silent and occur in different strains.
VOL. 48, 2010 AMINOGLYCOSIDE AND CAPREOMYCIN CROSS-RESISTANCE IN TB 405
FIG. 1. Frequency of observed polymorphisms observed in the M. tuberculosis isolates as a function of resistance to SM (A), KM (B), or CM
(C). The bars show the percentage of isolates with polymorphisms in the four indicated alleles or allele combinations that are fully susceptible
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found to be low-level KM/AK resistant (20 g/ml KM and
32 g/ml AK).
The correlation between ribosomal gene polymorphisms
and CM resistance. Two out of 5 high-level CM-resistant iso-
lates and 2 out of 13 moderately CM-resistant isolates showed
the rpsL(A128G) allele; however, 8 out of 89 fully CM-suscep-
tible strains also showed this allele and all four of the CM-
resistant isolates with rpsL polymorphisms were also highly
resistant to SM (Table 3). This suggests that the rpsL(A128G)
SNP is not associated with CM resistance. Likewise, the two
other observed rpsL alterations, at nt 51 and nt 363, were both
found in CM-sensitive strains and were therefore not associ-
ated with CM resistance.
Polymorphisms in helix 44 at nt 1401 were found in 4 out of
5 high-level CM resistant isolates as well as in 12 out of 13
moderately CM-resistant strains (Table 3 and Fig. 1C). All 16
strains carrying this SNP were resistant to CM, strongly sup-
porting that this SNP is associated with CM resistance (OR 
1,168, 95% CI  53 to 25,500, P  0.0001). SNPs at nt 1338
were present in 11 CM-sensitive strains and 5 out of 13 mod-
erately resistant strains but absent from all 5 of the highly
CM-resistant isolates, suggesting that this SNP was not asso-
ciated with CM resistance. Likewise, 5 out of 7 of the SNPs in
the pseudoknot region of helix 18 were in CM-sensitive strains
and the two isolates moderately resistant to CM with SNPs in
this region were both SM resistant. The rrs(C832T) allele was
fully CM susceptible. Interestingly, however, a single strain
with the double lesion in rrs at both nt 1445 and 1332 was
highly CM resistant. All the isolates found to be resistant to
CM in this strain collection were found to have at least one
SNP in the rrs gene.
Polymorphisms in tlyA and association with resistance to
CM. The tlyA gene was also sequenced in the entire set of
isolates. Several polymorphisms were detected, including a
ubiquitous codon 11 CTA-to-CTG transition that was found in
all isolates compared with the M. tuberculosis reference strain
H37Rv. Only three additional unique polymorphisms were
noted in this strain collection: tlyA144-155, tly(C152T) (codon
51 GCG3GTG [Ala-Val]), and tly(A344T) (codon 115
TAC3TTC [Tyr-Phe]). Notably, all three of these strains re-
mained fully CM susceptible.
Polymorphisms in gidB and association with low-level resis-
tance to SM. We determined the complete sequence of the
gidB gene for 97 isolates for which DNA amplification was
successful, including all those isolates resistant to the drugs
examined in this study, and detected a total of 18 differences in
comparison to the sequence of H37Rv. All of the isolates
showed a SNP at nt 299 with a T replacing the 299C allele in
the reported sequence of H37Rv. In addition, the majority of
isolates (n  83) contained an A3C SNP at nt 276 (codon 92
E3D). The 16 remaining polymorphisms were present at a
frequency of 0.227 (22 of 97). A deletion of G at nt 102, which
resulted in a frameshift at codon 34, was observed in four
samples, three of which were resistant to at least three drugs,
but only two of them showed low-level SM resistance, with an
MIC of 8 g/ml. These two samples also had two SNPs in the
rrs gene (1401 A3G and 1338 A3C). The third drug-resistant
sample that was SM susceptible had only the rrs (1401 A3G)
SNP in addition to the G102 deletion. The remaining fourth
sample had only the G102 deletion and was fully susceptible to
all drugs. Another isolate with a SM MIC of 32 g/ml had no
polymorphisms detected in the rpsL or rrs genes but had a 169
G3T SNP in gidB, which resulted in a stop signal at codon 57.
Two additional isolates had either a nt 341 T3C or a 440
A3C SNP causing amino acid changes in GidB in combination
with the rrs(A1338C) SNP and were resistant to 8 g/ml SM.
These two SNPs in gidB were not seen among the susceptible
isolates. Two isolates had C115 deletions and 1 isolate had a
G193 deletion, causing frameshifts at codons 39 and 65, re-
spectively, yet all isolates were susceptible to 4 g/ml SM.
Interestingly, two KM-resistant isolates that had no rrs poly-
morphism were found to have gidB polymorphisms (Table 3)
so it is possible that GidB activity can also influence KM
resistance. The remaining SNPs observed in the isolates sub-
stituted one amino acid for another in GidB in susceptible
strains. While we have observed a number of polymorphisms in
GidB in SM-resistant strains, some of these polymorphisms are
also found in susceptible strains so it is difficult to assess the
role of GidB in resistance to SM and KM with the data avail-
able. It will be necessary to construct these polymorphisms in
susceptible strains before we can draw firm conclusions.
(S) or resistant (R). The column representing susceptible isolates without a detected polymorphism describes 56 to 60% of isolates but has been
truncated at 15%. Category rrs 1401* includes those isolates with a polymorphism in this location as well as the single isolate with a double
polymorphism at rrs-1332 and -1445. (A) Isolates with the indicated codon 43 polymorphism in RpsL are significantly more likely to have high-level
drug resistance (P  0.0001) than isolates with other polymorphisms. (B and C) The resistance to KM and CM is most prevalent in isolates with
the A1401G transition or with both an rpsL gene polymorphism and an rrs polymorphism in the 1401 region (P  0.0001).
FIG. 2. Cross-resistance of isolates to injectable antibiotics. Pheno-
typic drug resistance of isolates diagrammed to depict overlapping
resistance pattern with any polymorphism profile. Each circle repre-
sents the set of isolates resistant to that drug. Isolates resistant to both
SM and KM are depicted within the overlap of those two circles.
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The predictive value of resistance-associated alleles in de-
termining sputum culture conversion. Ultimately the impor-
tance of a given clinical test is in the utility of such a test in
predicting the outcome of the clinical decision taken as a result
of a positive or negative finding of the test. In the case of drug
resistance, a test can be evaluated based upon whether the
result correlates with the outcome of the patients being
treated. In this case (a population of mostly MDR and some
XDR patients), we considered a successful outcome to be
sputum culture conversion by 4 months or less and a negative
outcome to be failure to achieve sputum culture conversion.
Since nearly all of these patients were being treated with amino-
glycosides, we explored the ability of the phenotypic DST using
two different methods (the absolute concentration and the
NCCLS methods) to predict the outcome in these patients.
There were 100 patients in this study with complete data on
sputum culture conversion (2 consecutive negative cultures
and no recurrence of a positive culture within the next 4
months). When one considers the outcome of treatment, a
finding of resistance for either KM or SM using the absolute
concentration method correlates with treatment failure only
53% of the time, whereas a finding of resistance using the
more accurate NCCLS method correlates with treatment
failure 69% of the time (Table 4). Likewise, the predictive
value of the test for a positive outcome can be estimated. In
the same way, a finding of either SM or KM resistance or
susceptibility from the molecular test (using the reported rrs
polymorphisms in helix 44 and the 530 pseudoknot and rpsL
128 alleles) can be compared with outcome and the three
tests can therefore be directly compared in terms of their
accuracy and predictive value. In terms of overall accuracy,
results of the molecular test and the NCCLS method are
indistinguishable at about 76% and clearly superior to those
of the absolute concentration method (67%). The three
methods have similar negative predictive values (i.e., a find-
ing of sensitive correlates well with treatment success) and
differ most strongly in their positive predictive values (i.e., a
finding of resistant correlates with failure). This allows one
to calculate a likelihood ratio for each of the tests that
estimates the fold increase in the probability that the test
can accurately predict the clinical result. In this calculation,
the molecular susceptibility test significantly outperforms
the commonly used absolute concentration method and is
equivalent to the NCCLS MIC method.
DISCUSSION
Establishing causality for SNPs observed in drug-resistant
clinical isolates of MDR TB is nontrivial; the often incomplete
treatment history of subjects and the inaccuracy of phenotypic
DST for second-line agents lead to the potential for misinter-
pretation of observed SNPs as functional when they in fact
represent natural sequence variation. In many cases, it can also
be difficult to establish whether the observed polymorphism
represents the mutation that gave rise to resistance or a com-
pensatory mutation selected afterward to improve fitness of
the resistant isolate (9). Selection of single-step resistant mu-
tants in vitro can facilitate this process but in many cases gives
rise to mutations that are not representative of the situation in
vivo during infection. Comparing the results of the two differ-
ent selective environments offers some hope to rationalize the
observed resistance. For example, in this study we found that
the majority of KM-resistant isolates from this subject cohort
that were resistant to KM were also resistant to AK and CM
and the majority of these isolates showed the 1401 A3G
transition (Fig. 2). In fact 16 out of 16 isolates with this poly-
morphism were resistant to KM and were fully cross-resistant
to AK and CM. This is in accordance with previous reports that
have selected for in vitro mutants, either simultaneously or
sequentially, to combinations of these drugs and have observed
similar causality of the 1401 allele (19). In addition, this SNP is
biologically plausible as this polymorphism occurs very near to
the known binding site for KM (Fig. 3). For this allele, there-
fore, we can be fairly confident in predicting that the SNP at nt
1401 conferred resistance to all three drugs. Unfortunately,
even in this relatively small strain collection, more than 15% (3
of 20 strains) do not have this SNP yet are highly resistant to
one of these agents.
Likewise, our finding that the most common polymorphism
associated with SM resistance was the A128G substitution in
rpsL is consistent with many previous reports from both in vitro
and clinical samples (26, 27). The location of this polymor-
phism on the bacterial ribosome is likewise very close to the
binding site for SM, making this also biochemically reasonable
TABLE 4. Predictive value of phenotypic and molecular drug susceptibility testing (DST) for 4-month sputum culture conversiona
DST method
and result
No. with treatment
outcome Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%) Likelihoodratio
Success Failure
MIC
Sensitive 52 11
Resistant 11 25 69.5 82.5 72.6 69.4 82.5 4.0
Critical concn
Sensitive 38 6
Resistant 26 29 82.9 59.4 37.2 52.7 86.4 2.0
Genotyping
Sensitive 53 13
Resistant 10 23 63.8 84.1 71.6 69.7 80.3 4.0
a PPV, positive predictive value; NPV, negative predictive value; likelihood ratio  sensitivity/(1specificity).
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(Fig. 3). Many other studies have also focused on the role of rrs
alterations in the 530 loop region similar or identical to the
ones described here that appear to be associated with SM
resistance (25). It is noteworthy that the 530 loop region is very
close in space to the lysine at position 43 of RpsL in the crystal
structure and substitutions here are therefore likely to exert a
direct effect on drug binding. Confirmation of the causality of
these polymorphisms in the 530 loop region will require mov-
ing these specific changes into isogenic strains.
What was striking in this sample set was the extent of poly-
morphism in the gidB gene. GidB was identified as an S-
adenosyl-L-methionine (SAM)-dependent, rRNA methyl-
transferase associated with low-level SM resistance (22, 24).
The GidB protein mediates methylation of G527, another res-
idue in the 530 pseudoknot that may affect the SM binding site
directly (22). We saw 15 different polymorphisms in gidB
among 21 isolates, including drug-sensitive as well as drug-
resistant strains. Most of these polymorphisms mapped to con-
served residues of the protein, including the SAM-binding site.
Interestingly, the G102 deletion occurred in four different
strains and was the only polymorphism that was also observed
by others in both SM-resistant and SM-susceptible clinical
strains (22, 24). Further investigation is needed to probe the
association between the G102 deletion, the resultant frame-
shift at codon 34, and SM susceptibility. It seems rather un-
likely that polymorphisms in highly conserved regions of this
protein that methylates rRNA very close to the binding site for
SM are unrelated to drug selective pressure; however, our
analysis using standard DST methodology does not provide
any direct confirmation of this prediction. In contrast to the
observation by Okamoto et al. (22) that some isolates carrying
a gidB polymorphism were both SM and KM resistant, despite
lacking the rrs(A1401G) SNP, we did not observe this same
genetic profile in the present set of isolates, although we did
identify two isolates with gidB polymorphisms that were KM
resistant and SM susceptible in the absence of the rrs(A1401G)
SNP. Thus, at present, we have no evidence supporting the
possibility that gidB polymorphisms may mediate some level of
cross-resistance between SM and KM.
This study did identify a potential new double polymorphism
FIG. 3. The location of polymorphisms identified in this study on components of the bacterial ribosome. The structures of the 16S rRNA and
RpsL from Thermus thermophilus (Protein Data Base no. 2hgr) were used to construct this schematic (produced using Discovery Studio 2.0,
Accelrys). The ribosomal A, P, and E sites that form the active center of the complex are shaded pink, yellow, and blue, respectively. The RpsL
protein is shown in ribbon form. The 530 loop region is shown as green balls and sticks. Numbering shown is according to the T. thermophilus
convention followed by the corresponding position in the M. tuberculosis sequence. Polymorphisms observed in this study of rrs are colored blue
and those of rpsL in pink.
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in the 3 minor domain that may be associated with low-level
KM/AK/CM cross-resistance, rrs(A1445G, G1332A). Confir-
mation of this will require allelic exchange in congenic strains.
Notably, A1332 is located in the middle of the P site (Fig. 3),
suggesting a possible effect on overall catalytic rates of protein
synthesis that may confer relative drug insensitivity. Perhaps
more importantly, we have identified two strains with resis-
tance to the 2-deoxystreptamines for which there are no ap-
parent polymorphisms in genes other than gibB. If this can be
established, the basis for the molecular resistance of these two
strains will help to improve the sensitivity of a molecular ap-
proach to diagnosing XDR disease. There are also a consid-
erable number of strains for which SM resistance cannot be
explained. Of the 26 moderately to highly resistant isolates, 8
do not contain polymorphisms in either the 530 loop of rrs or
the RpsL protein.
CM is the agent for which the least is known in terms of
resistance mechanisms in clinical isolates. Transposon mu-
tagenesis of tlyA (Rv1694) in M. tuberculosis resulted in CM-
resistant colonies that when complemented with wild-type tlyA
recovered susceptibility to the drug (20). The tlyA gene en-
codes a 2-O-methyltransferase that creates methylations in
helix 44 of the 16S and helix 69 of the 23S rRNA. When the
ribosomal subunits form a complex, these methylations are
brought together, creating the binding site of CM, which, once
bound, inhibits ribosome translocation. Loss of function of tlyA
or mutation of its targets confers resistance to CM. Due to
scarce use of CM in this population, SNPs in the tlyA gene
associated with CM resistance were not observed. There re-
mains the possibility that patients resistant to KM but lacking
a SNP in rrs in the region of nt 1401 will still be sensitive to CM
even though in this cohort it appears that this is rare. It also
appears as though the strong selection presented by KM/AK
use generates very high levels of CM cross-resistance, limiting
the utility of this drug in this patient population.
As elegantly shown in vitro, both the order and the concen-
tration of the drug selective pressure make a difference on the
mutations observed (19). In the context of the isolates exam-
ined in this study, CM is relatively rarely used due to availabil-
ity of this agent in South Korea and its expense; therefore,
KM/AK and SM have exerted the predominant selective pres-
sure. These results therefore not only expand our knowledge of
the extent of cross-resistance between various ribosomal inhib-
itors that have been used clinically but also suggest that some
additional thought might be appropriate for the order of drug
addition in selecting patient regimens. CM, for example, might
be better added prior to treatment with KM or AK, since
resistance to CM (if generated via tlyA) may be less likely to
give cross-resistance to the 2-deoxystreptamines, whereas ap-
plication of KM and AK seems to result predominantly in
mutations that confer cross-resistance to CM.
ACKNOWLEDGMENTS
We sincerely thank the many patients that have been willing to
sacrifice their time and energy to contribute to this study and the
doctors and nurses of the National Masan Tuberculosis Hospital that
made this work possible.
Funding for this work was provided (in part) by the Intramural
Research Program of the NIH, NIAID; (in part) by continuing support
from the Ministry for Health, Welfare and Family Affairs of the Re-
public of Korea; and (in part) by the Korea Foundation for Interna-
tional Cooperation for Science and Technology (KICOS) through a
grant provided by the Ministry of Education and Science and Tech-
nology of the Republic of Korea.
REFERENCES
1. Alangaden, G. J., B. N. Kreiswirth, A. Aouad, M. Khetarpal, F. R. Igno, S. L.
Moghazeh, E. K. Manavathu, and S. A. Lerner. 1998. Mechanism of resis-
tance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimi-
crob. Agents Chemother. 42:1295–1297.
2. Antonova, O. V., D. A. Gryadunov, S. A. Lapa, A. V. Kuz’min, E. E. Lari-
onova, T. G. Smirnova, E. Y. Nosova, O. I. Skotnikova, L. N. Chernousova,
A. M. Moroz, A. S. Zasedatelev, and V. M. Mikhailovich. 2008. Detection of
mutations in Mycobacterium tuberculosis genome determining resistance to
fluoroquinolones by hybridization on biological microchips. Bull. Exp. Biol.
Med. 145:108–113.
3. Bwanga, F., S. Hoffner, M. Haile, and M. L. Joloba. 2009. Direct suscepti-
bility testing for multi drug resistant tuberculosis: a meta-analysis. BMC
Infect. Dis. 9:67.
4. Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, N. K. Menon, D. A.
Mitchison, N. Rist, and N. A. Smelev. 1969. Advances in techniques of
testing mycobacterial drug sensitivity, and the use of sensitivity tests in
tuberculosis control programmes. Bull. World Health Organ. 41:21–43.
5. Canetti, G., S. Froman, J. Grosset, P. Hauduroy, M. Langerova, H. T.
Mahler, G. Meissner, D. A. Mitchison, and L. Sula. 1963. Mycobacteria:
laboratory methods for testing drug sensitivity and resistance. Bull. World
Health Organ. 29:565–578.
6. Carter, A. P., W. M. Clemons, D. E. Brodersen, R. J. Morgan-Warren, B. T.
Wimberly, and V. Ramakrishnan. 2000. Functional insights from the struc-
ture of the 30S ribosomal subunit and its interactions with antibiotics. Nature
407:340–348.
7. Chan, E. D., and M. D. Iseman. 2008. Multidrug-resistant and extensively
drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis. 21:587–595.
8. Donald, P. R., and P. D. van Helden. 2009. The global burden of tubercu-
losis–combating drug resistance in difficult times. N. Engl. J. Med. 360:2393–
2395.
9. Gagneux, S., C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, and B. J.
Bohannan. 2006. The competitive cost of antibiotic resistance in Mycobac-
terium tuberculosis. Science 312:1944–1946.
10. Grandjean, L., and D. A. Moore. 2008. Tuberculosis in the developing world:
recent advances in diagnosis with special consideration of extensively drug-
resistant tuberculosis. Curr. Opin. Infect. Dis. 21:454–461.
11. Hillemann, D., S. Rusch-Gerdes, and E. Richter. 2009. Feasibility of the
GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and
ethambutol resistance testing of Mycobacterium tuberculosis strains and
clinical specimens. J. Clin. Microbiol. 47:1767–1772.
12. Hillemann, D., M. Weizenegger, T. Kubica, E. Richter, and S. Niemann.
2005. Use of the genotype MTBDR assay for rapid detection of rifampin and
isoniazid resistance in Mycobacterium tuberculosis complex isolates. J. Clin.
Microbiol. 43:3699–3703.
13. Jeon, C. Y., S. H. Hwang, J. H. Min, D. R. Prevots, L. C. Goldfeder, H. Lee,
S. Y. Eum, D. S. Jeon, H. S. Kang, J. H. Kim, B. J. Kim, D. Y. Kim, S. M.
Holland, S. K. Park, S. N. Cho, C. E. Barry III, and L. E. Via. 2008.
Extensively drug-resistant tuberculosis in South Korea: risk factors and treat-
ment outcomes among patients at a tertiary referral hospital. Clin. Infect.
Dis. 46:42–49.
14. Jeon, D. S., D. H. Kim, H. S. Kang, S. H. Hwang, J. H. Min, J. H. Kim, N. M.
Sung, M. W. Carroll, and S. K. Park. 2009. Survival and predictors of
outcomes in non-HIV-infected patients with extensively drug-resistant
tuberculosis. Int. J. Tuberc. Lung Dis. 13:594–600.
15. Kim, D. H., H. J. Kim, S. K. Park, S. J. Kong, Y. S. Kim, T. H. Kim, E. K.
Kim, K. M. Lee, S. S. Lee, J. S. Park, W. J. Koh, C. H. Lee, J. Y. Kim, and
T. S. Shim. 2008. Treatment outcomes and long-term survival in patients
with extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med.
178:1075–1082.
16. Kim, S. J. 2005. Drug-susceptibility testing in tuberculosis: methods and
reliability of results. Eur. Respir. J. 25:564–569.
17. Kocagoz, T., E. Yilmaz, S. Ozkara, S. Kocagoz, M. Hayran, M. Sachedeva,
and H. F. Chambers. 1993. Detection of Mycobacterium tuberculosis in
sputum samples by polymerase chain reaction using a simplified procedure.
J. Clin. Microbiol. 31:1435–1438.
18. Lacoma, A., N. Garcia-Sierra, C. Prat, J. Ruiz-Manzano, L. Haba, S. Roses,
J. Maldonado, and J. Dominguez. 2008. GenoType MTBDRplus assay for
molecular detection of rifampin and isoniazid resistance in Mycobacterium
tuberculosis strains and clinical samples. J. Clin. Microbiol. 46:3660–3667.
19. Maus, C. E., B. B. Plikaytis, and T. M. Shinnick. 2005. Molecular analysis of
cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in My-
cobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192–3197.
20. Maus, C. E., B. B. Plikaytis, and T. M. Shinnick. 2005. Mutation of tlyA
confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob.
Agents Chemother. 49:571–577.
21. Mokrousov, I., T. Otten, O. Manicheva, Y. Potapova, B. Vishnevsky, O.
Narvskaya, and N. Rastogi. 2008. Molecular characterization of ofloxacin-
410 VIA ET AL. J. CLIN. MICROBIOL.
resistant Mycobacterium tuberculosis strains from Russia. Antimicrob.
Agents Chemother. 52:2937–2939.
22. Okamoto, S., A. Tamaru, C. Nakajima, K. Nishimura, Y. Tanaka, S. To-
kuyama, Y. Suzuki, and K. Ochi. 2007. Loss of a conserved 7-methyl-
guanosine modification in 16S rRNA confers low-level streptomycin resis-
tance in bacteria. Mol. Microbiol. 63:1096–1106.
23. Raviglione, M. C., and I. M. Smith. 2007. XDR tuberculosis–implications for
global public health. N. Engl. J. Med. 356:656–659.
24. Spies, F. S., P. E. da Silva, M. O. Ribeiro, M. L. Rossetti, and A. Zaha. 2008.
Identification of mutations related to streptomycin resistance in clinical
isolates of Mycobacterium tuberculosis and possible involvement of efflux
mechanism. Antimicrob. Agents Chemother. 52:2947–2949.
25. Springer, B., Y. G. Kidan, T. Prammananan, K. Ellrott, E. C. Bottger, and
P. Sander. 2001. Mechanisms of streptomycin resistance: selection of muta-
tions in the 16S rRNA gene conferring resistance. Antimicrob. Agents Che-
mother. 45:2877–2884.
26. Sreevatsan, S., X. Pan, K. E. Stockbauer, D. L. Williams, B. N. Kreiswirth,
and J. M. Musser. 1996. Characterization of rpsL and rrs mutations in
streptomycin-resistant Mycobacterium tuberculosis isolates from diverse
geographic localities. Antimicrob. Agents Chemother. 40:1024–1026.
27. Sun, Y. J., J. T. Luo, S. Y. Wong, and A. S. Lee. 6 June 2009, posting date.
Analysis of rpsL and rrs mutations in Beijing and non-Beijing streptomycin-
resistant Mycobacterium tuberculosis isolates from Singapore. Clin. Micro-
biol. Infect. doi:10.1111/j.1469–0691.2009.02800.
28. van Doorn, H. R., D. D. An, M. D. de Jong, N. T. Lan, D. V. Hoa, H. T. Quy,
N. V. Chau, P. M. Duy, D. Q. Tho, N. T. Chinh, J. J. Farrar, and M. Caws.
2008. Fluoroquinolone resistance detection in Mycobacterium tuberculosis
with locked nucleic acid probe real-time PCR. Int. J. Tuber. Lung Dis.
12:736–742.
29. Wayne, L. G. 1974. Simple pyrazinamidase and urease tests for routine
identification of mycobacteria. Am. Rev. Respir. Dis. 109:147–151.
30. Woods, G. L. 2000. Susceptibility testing for mycobacteria. Clin. Infect. Dis.
31:1209–1215.
VOL. 48, 2010 AMINOGLYCOSIDE AND CAPREOMYCIN CROSS-RESISTANCE IN TB 411
